Glucagon stimulates phosphorylation of different peptides in isolated periportal and perivenous hepatocytes  by Aggarwal, Shashi R. et al.
FEBS 16458 FEBS Letters 377 (1995) 439443 
Glucagon stimulates phosphorylation of different peptides in isolated 
periportal and perivenous hepatocytes 
Shashi R. Aggarwal a'*, Kai O. Lindros b, T. Norman Palmer a
~Department of Biochemistry, University of Western Australia, Nedlands, Western Australia 6907, Australia 
bBiomedical Research Centre, Alko Group Ltd.. Box 350, Helsmki, Finland 
Received 10 November 1995 
Abstract The perivenous and periportal zones of the liver acinus 
differ in enzyme complements and capacities for gluconeogenesis, 
glycolysis and other metabolic processes. The biochemical factors 
governing this metabolic zonation are still poorly understood. 
Glueagon-mediated protein phosphorylation is an important fac- 
tor in the regulation of hepatic metabolism. Here we show, by 
comparing the 32P-lahelling pattern of isolated periportal and 
perivenous hepatocytes, that glucagon promotes the phosphoryla- 
tion of zone-specific peptides as well as three common peptides 
(glycogen phosphorylase, glycogen synthase and pyruvate kinase) 
in the two cell types. We propose that the zone-specific phospho- 
rylation of peptides is an important factor governing the short- 
term zonation of metabolic processes in the liver. 
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1. Introduction 
Hepatocytes from the perivenous and periportal zones of the 
microcirculatory unit of the liver, the acinus, differ in their 
enzyme complements and subcellular structures [1]. The peri- 
portal hepatocytes, which are exposed to more oxygenated 
blood rich in absorbed nutrients, possess a greater mitochon- 
drial volume (20% by volume) and have higher activities of 
mitochondrial enzymes than perivenous hepatocytes. In func- 
tional terms, the periportal hepatocytes have higher activities 
of gluconeogenic enzymes (pyruvate carboxylase, 
phosphoenolpyruvate carboxykinase, fructose 1,6-bis- 
phosphatase and glucose 6-phosphatase) and oxidative and tri- 
carboxylic acid (TCA) cycle enzymes, whereas perivenous 
hepatocytes have higher activities of glycolytic enzymes (glu- 
cokinase, fructose 6-phosphate 1-kinase and pyruvate kinase), 
lipogenic enzymes (ATP-citrate lyase, acetyl CoA carboxylase 
and fatty acid synthase) and ketogenic enzymes. All hepato- 
cytes within the acinus possess the machineries for glycogen 
synthesis and degradation (glycogen phosphorylase and glyco- 
gen synthase) and also the capacity for the synthesis and degra- 
dation of the regulatory metabolite fructose 2,6-bisphosphate 
via the bifunctional enzyme 6-phosphofructo-2-kinase/fructose 
2,6-bisphosphatase (h reafter referred as fructose 6-phosphate 
2-kinase) [2]. Periportal hepatocytes have a greater capacity for 
glycogen synthesis from gluconeogenic precursors than peri- 
venous hepatocytes [3], raising the possibility that zonation is 
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a major factor determining the relative contributions of the 
direct and indirect pathways to hepatic glycogen synthesis. 
Many biochemical processes in the liver are regulated by 
reversible protein phosphorylation. Glucagon promotes he- 
patic glycogenolysis and gluconeogenesis v a phosphorylation 
of glycogen phosphorylase, glycogen synthase, fructose 6-phos- 
phate 2-kinase and pyruvate kinase. Cytosolic peptides in the 
liver that are phosphorylated in response to acute challenge 
with glucagon have been identified by one- and two-dimen- 
sional electrophoresis [4-10]. A number of these proteins, in- 
cluding pyruvate kinase and fructose 1,6-bisphosphatase, are
expressed at different levels in periportal and perivenous hepa- 
tocytes. Although periportal and perivenous hepatocytes both 
possess receptors and the signalling pathway for glucagon 
[3,11,12], they may differ in their sensitivity to glucagon either 
as a result of a periportal-perivenous glucagon gradient across 
the acinus or from other factors. In this context, glycogen 
degradation i periportal hepatocytes is more sensitive to stim- 
ulation by glucagon compared to perivenous hepatocytes [13]. 
Histochemical studies [14,15] suggest that this greater sensitiv- 
ity may be the consequence of higher glycogen phosphorylase 
activities in the periportal zone, although studies on freshly 
isolated periportal and perivenous hepatocytes show no differ- 
ences in glycogen phosphorylase activities [11]. The question as 
to what extent differences in glucagon sensitivity might be ex- 
erted at the level of protein phosphorylation has not been 
addressed before. In this paper we have compared isolated 
periportal and perivenous heptocytes with respect o their sen- 
sitivity to glucagon-stimulated phosphorylation of cytosolic 
proteins identified by one-dimensional SDS-PAGE. 
2. Materials and methods 
2.1. Chemicals 
Reagents were obtained from the sources specified in[10]. The Micro 
BCA protein assay reagent kit was purchased from Pierce (Rockford, 
lllinios, USA), whereas digitonin and RQ1 RNase-free DNase (deoxy- 
ribonuclease) were obtained from the Sigma Chemical Company (St. 
Louis, Mo, USA). Alanine aminotransferase activity was measured 
using the ALT (ALAT/GPT) kit from Boehringer Mannheim GmbH 
(Mannheirn, Germany). 
2.2. Glucagon challenge of 32P-labelled periportal and perivenous 
hepatocytes and the isolation of the cytosolic protein fraction 
Periportal and perivenous hepatocytes were isolated from fed male 
Wistar rats (150-200 g) by site-specific digitonin cell lysis followed by 
collagenase perfusion as described by Lindros and Penttilft [16]. The 
crude cell suspension was briefly treated with DNase in bicarbonate/ 
Hepes buffer at pH 7.4 followed by centrifugation twice at 400 x g for 
20 s and filtration of the cell suspension using nylon mesh (100 pm). 
Cell viability, assessed by exclusion of Trypan blue, ranged between 
85-95%. Isolated periportal hepatocytes were confirmed to have alan- 
ine aminotransferase ctivities at least wice those of perivenous cells. 
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The final pellet (2~4 x l0 n cells/ml) was suspended in a low-phosphate 
(0.1 mM) Krebs-Ringer bicarbonate buffer containing 16 mM L-lactate 
and 4 mM pyruvate as described by Garrison and Wagner [6]. 
The hepatocyte preparations were first labelled with 32po~ (0.5 mCi) 
in a shaking waterbath (37°C) for 45 min to incorporate 32P-label into 
the intracellular ATP pool [10]. The cells were challenged with different 
concentrations of glucagon (10 ~2 to 10 -~ M) for 5 min. Thereafter, the 
cells suspension was diluted 2-fold in digitonin fractionation buffer (4 
mg/ml digitonin in 10 mM TES at pH 7.4 containing 50 mM NaF, 10 
mM EDTA, 5 mM EGTA and 200 mM sucrose) and centrifuged at 
13,000 × g for 6-8 s to terminate the reaction and release cytosolic 
proteins [10]. The cytosolic fractions were prepared by boiling the 
cytosolic proteins immediately for 5 rain in SDS buffer (0.0625 M 
Tris-HCl, pH 6.8 containing 10% (v/v) glycerol, 5% (v/v) 2-mercap- 
toethanol, 2% (w/v) SDS and 0.001% (w/v) Bromophenol blue). 
2.3. One-dimensional ge electrophoresis and densitometric analysis 
The cytosolic protein traction was resolved by one-dimensional SDS- 
PAGE by a modification of the method of Laemmli [17] using a 5 to 
15% (w/v) linear gradient acrylamide resolving gel and a 4% (w/v) 
stacking el. The use of linear gradients of acrylamide was found to 
increase resolution of low and high molecular mass peptides. Samples 
of the cytosol fraction (20/2g protein) were loaded onto polyacrylamide 
gels and electrophoresed [10]. Gels were then stained, destained and 
vacuum dried in a gel drier and the dried gels exposed on a Fujix 
Phosphor Imaging casette for approx. 24 h. The resultant images were 
scanned on a Fujix BAS 1000 Phosphor Imager using the MacBas 
V1.01 programme and the 32p-labelled phosphopeptides were analysed 
densitometrically using the NIH Image V1.57 programme. The protein 
content of cytosolic fractions was determined by the Micro BCA pro- 
rein assay reagent kit. The molecular masses of individual peptides were 
determined as described in [10]. 
2.4. Calculation and expression of results 
The extent of phosphorylation f the different peptides in response 
to glucagon challenge in isolated periportal and perivenous hepatocytes 
was determined by comparison to controls (no glucagon) for six sepa- 
rate experiments, the results being expressed as means _+ S.E.M. The 
statistical significance of differences between groups of data was deter- 
mined by ANOVA. 
3. Resu l ts  
3.1. Identi O' of the peptides phosphorylated in response to acute 
glucagon challenge in periportal and perivenous hepatocytes 
Previous research based on mixed rat hepatocytes i olated by 
conventional techniques [10] has established that glucagon con- 
sistently stimulates the phosphorylat ion of a number  of  cy- 
tosolic peptides, including the ~- and fl-subunits of glycogen 
phosphorylase kinase, glycogen phosphorylase, glycogen syn- 
thase, pyruvate kinase, fructose 6-phosphate 2-kinase, phenyla- 
lanine hydroxylase, fructose 1,6-bisphosphatase and r ibosomal 
protein $6 as well as two as yet unidentified peptides with 
molecular masses of 48 kDa and 46 kDa. In the present study, 
the phosphorylat ion of these peptides was compared in isolated 
periportal and perivenous hepatocytes after challenge with dif- 
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Fig. 1. Typical phosphor images of the cytosolic peptides phosphorylated in response to different concentrations ofglucagon (10 ~2 10-7 M) in isolated 
(A) periportal and (B) perivenous hepatocytes. The phosphor images of the one-dimensional gels show approximately thirty cytosolic 32p-labelled 
peptides making it difficult to see changes in the ~:P-labelling of individual peptides, particularly those present as minor components. To overcome 
this problem, the figure shows only the images of those bands that correspond to peptides with molecular masses of (1) 123, (2) 93, (3) 85, (4) 61, 
(5) 55, (6) 52, (7) 48, (8) 46, (9) 42 and (10) 34 kDa (see text for details). C refers to control/no glucagon). 
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Fig. 2. The phosphorylation f cytosolic peptides in response to differ- 
ent concentrations of glucagon ( 10- ~ z 10 ° M ) in isolated periportal nd 
perivenous hepatocytes. The results hown are means + S.E.M. for six 
separate xperiments, he extent of ~:P-labelling ofthe individual pep- 
tides being expressed asincreases (%) above basal (no glucagon) values. 
The phosphopeptides shown are glycogen phosphorylase (D), glycogen 
synthase (o), pyruvate kinase (~;), phenylalanine hydroxylase (~), fruc- 
tose 1,6-bisphosphatase (m),the/3-subunit ofglycogen phosphory[ase 
kinase (v), fructose 6-phosphate 2-kinase (v), ribosomal protein $6 ( * ) 
and two as yet unidentified peptides of molecular masses of 48 kDa (A) 
and 46 kDa (<>). 
ferent concentrations of glucagon (10 -~-~ 10 7 M) that encom- 
pass the physiological range (10 ~' 10 -s M). 
When cytosolic protein fractions from both periportal and 
perivenous hepatoeytes were subjected to one-dimensional 
SDS-PAGE, at least forty-five peptide bands were consistently 
detected after Coomassie blue-staining. Approximately thirty 
of these peptides incorporated ;2p during pre-equilibration with 
32po3-. Many, but not all, of the peptides howed higher basal 
(no glucagon) phosphorylation in perivenous compared to peri- 
portal hepatocytes (Fig. 1). This higher basal phosphorylation 
may reflect differences in endogenous protein kinase and pro- 
tein phosphatase activities between the two cell types. Glu- 
cagon was found to increase the phosphorylation f different 
subsets of peptides in periportal and perivenous hepatocytes 
(Figs. 1 and 2). Glucagon stimulated the phosphorylation f six 
cytosolic peptides with molecular masses of 93, 85, 61, 52, 42 
and 48 kDa in periportal hepatocytes. The molecular masses 
of these 32p-labelled phosphopeptides were highly reproducible 
and agree closely with our previously published studies [10], 
allowing identification of five of these phosphopeptides as gly- 
cogen phosphorylase (93 kDa), glycogen synthase (85 kDa), 
pyruvate kinase (61 kDa), phenylalanine hydroxylase (52 kDa) 
and fructose 1,6-bisphosphatase (42 kDa). The 48 kDa 
phosphopeptide r mains unidentified. By contrast, glucagon 
stimulated the phosphorylation f seven peptides of molecular 
masses of 123, 93, 85, 61, 55, 34 and 46 kDa in perivenous 
hepatocytes (Figs. 1 and 2). Only three of peptide substrates 
(glycogen phosphorylase; 93 kDa, glycogen synthase; 85 kDa 
and pyruvate kinase; 61 kDa) are the same as those 
phosphorylated in periportal hepatocytes. Our previous tudies 
[10] indicate that of the other four three correspond to the 
fl-subunit of glycogen phosphorylase kinase (123 kDa), fruc- 
tose 6-phosphate 2-kinase (55 kDa) and ribosomal protein $6 
(34 kDa), respectively, whereas the 46 kDa phosphopeptide 
remains unidentified. 
3.2. Extent and concentration-dependency of glucagon- 
stimulated peptide phosphorylation i  periportal and 
perivenous hepatocytes 
There were differences between periportal and perivenous 
hepatocytes not only in the subsets of cytosolic peptides 
phosphorylated in response to glucagon challenge but also in 
the extent of the stimulation of this phosphorylation (Table 1), 
including that of the common peptide substrates. In periportal 
hepatocytes glucagon at 10 -7 M (compared to 10 -t2 M) in- 
creased the phosphorylation f glycogen phosphorylase, glyco- 
gen synthase and pyruvate kinase by 107%, 82% and 11%, 
respectively, whereas in perivenous hepatocytes it increased the 
phosphorylation of these peptides by 18%, 29% and 107%, 
respectively. Thus, although glucagon stimulates the phospho- 
rylation of common substrates in periportal and perivenous 
hepatocytes, the extent of phosphorylation f these substrates 
is significantly different (P < 0.001 ) between the two cell types. 
Peptides also differed in their responsiveness to glucagon at 
different concentrations. Half-maximal phosphorylation (ECs0) 
of the peptides occurred at 1 x 10 -~° to 4 × 10 -9 M glucagon, 
except hat the glucagon response curves of phenylalanine hy- 
droxylase in periportal hepatocytes and those of glycogen 
phosphorylase and glycogen synthase in perivenous hepato- 
cytes were flattened (Table 1). 
4. Discussion 
This paper represents the first systematic attempt to quanti- 
tare the impact of hepatic zonation on the responsiveness of
cytosolic peptides to glucagon-stimulated protein phosphoryla- 
tion. One-dimensional SDS-PAGE of 32P-labelled cytosolic 
peptides from periportal and perivenous rat hepatocytes pre- 
equilibrated with 32PO~- indicates that glucagon stimulates the 
phosphorylation f different subsets of peptides in the two cell 
populations. Whereas glucagon promotes the phosphorylation 
of phenylalanine hydroxylase, fructose 1,6-bisphosphatase nd 
an as yet unidentified 48 kDa phosphopeptide in periportal 
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Table 1 
Identity of the cytosolic peptides phosphorylated in response to glucagon in periportal nd perivenous hepatocytes and the extent and ECs0 of their 
phosphorylation 
Identified proteins Molecular mass Increase in phosphorylation (%) ECs0 (x 10 -t° M) 
(kDa) 
PP PV PP PV 
Phosphorylase kinase fl-subunit 123 nd 25 + 1 fr 
Glycogen phosphorylase 93 107 _+ 2 ~ 18 + 1 "x 20 fr 
Glycogen synthase 85 82 + 2 b 29 _+ 1 b~ 40 fr 
Pyruvate kinase 61 11 +_ 1 107 _+ 2 b fr 9 
Fructose 6-phosphate 2-kinase 55 nd 118 + 2 b 1 
Phenylalanine hydroxylase 52 37 + 1 ~ nd 2 - 
Unidentified protein 48 90 _+ 2 b nd 30 - 
Unidentified protein 46 nd 117 + 2 b 8 
Fructose 1,6-bisphosphatase 42 83 _+ 2 b nd 4 
Ribosomal protein $6 34 nd 75 + 2 20 
Statistically significant increases in phosphorylation at 10 ~2 M glucagon (expressed as means + S.E.M. relative to 10 -12 M glucagon) are denoted 
as "P < 0.01 and bp ~ 0.001, whereas differences in the extent of phosphorylation f the two common phosphopeptide substrates (glycogen 
phosphorylase and glycogen synthase) between periportal nd perivenous hepatocytes are denoted as cp < 0.001. nd denotes not detected inrespective 
hepatocytes. EC~ refers to the glucagon concentrations giving half-maximal phosphorylation, whereas fr denotes that the glucagon response curve 
was flattened. 
hepatocytes, it stimulates the phosphorylation f the fl-subunit 
of glycogen phosphorylase kinase, fructose 6-phosphate 2-ki- 
nase, ribosomal protein $6 and an as yet unidentified 46 kDa 
phosphopeptide in perivenous hepatocytes. In addition to these 
zone-specific peptides, glucagon stimulates the phosphoryla- 
tion of three common substrates (glycogen phosphorylase, gly- 
cogen synthase and pyruvate kinase) in both cell types, albeit 
to significantly different extents. The identities of the glucagon- 
stimulated phosphopeptides have been previously confirmed by 
two-dimensional SDS-PAGE [10]. 
The major question raised by this study is why the zonal 
patterns of phosphorylation of at least certain enzymes (fruc- 
tose 1,6-bisphosphatase, fructose 6-phosphate 2-kinase, py- 
ruvate kinase and glycogen phosphorylase) do not coincide 
with the reported zonal distributions of their activities. Fruc- 
tose 1,6-bisphosphatase nd pyruvate kinase, for example, are 
reported, respectively, to be largely, but not exclusively, peri- 
portal (60-78%) and perivenous (55%) in location [2,12,18-21]. 
whereas our results indicate that their phosphorylation is exclu- 
sively periportal or perivenous, respectively (Table 1). There is 
also a discrepancy between the reported equal capacities of 
periportal and perivenous hepatocytes for the synthesis and 
degradation of fructose 2,6-bisphosphate [2] and our finding 
that the phosphorylation of fructose 6-phosphate 2-kinase is 
exclusively perivenous in location. Similarly, we show that the 
glucagon-stimulated phosphorylation of glycogen phosphory- 
lase is substantially greater in isolated periportal than in peri- 
venous hepatocytes, whereas studies on isolated hepatocytes 
[11] indicate that glycogen phosphorylase activity is evenly dis- 
tributed between the two cell populations. These findings raise 
the intriguing question of whether zonal differences in phos- 
phorylation may constitute a mechanism to explain the short- 
term dynamic zonation of glycolysis, gluconeogenesis and other 
metabolic processes. This mechanism proposes that the zona- 
tion of these biochemical processes is determined by zonal 
differences in sensitivity to phosphorylation rather than zonal 
differences in the distribution of the target enzymes per se. This 
hypothesis raises the question of the identity of the factor(s) 
that determine zonal differences in sensitivity to glucagon. Both 
periportal and perivenous hepatocytes possess glucagon recep- 
tors and the machinery for glucagon signalling via cyclic AMP 
and cyclic AMP-dependent protein kinase, although there may 
be a periportal-perivenous gradient in glucagon concentrations 
and in glucagon receptor density across the acinus. The infer- 
ence is that differences in glucagon signalling via cyclic AMP 
are not the primary factors governing zonal differences in phos- 
phorylation. One factor that may account for the apparent 
zonal differences in sensitivity to glucagon may relate to differ- 
ences in the activities of protein phosphatases, particularly pro- 
tein phosphatases 1 and 2A. Another factor may be the levels 
of regulatory metabolites that modulate glucagon-stimulated 
phosphorylation. The cyclic AMP-dependent inactivation of 
L-type pyruvate kinase is inhibited by phosphoenolpyruvate 
and fructose 1,6-bisphosphate, effects that are counteracted by 
Mg-ATP and certain amino acids [22-24]. The implication is 
that effectors that alter the conformation of regulatory proteins 
may alter their susceptibility o phosphorylation. Thus, if the 
levels of regulatory metabolites were to differ between peripor- 
tal and perivenous hepatocytes, the possibility exists that these 
levels determine phosphorylation i  the different cell popula- 
tions. One other factor that may influence the 32p-labelling of 
peptides in response to glucagon may be the level of occupancy 
of phosphorylation sites on peptides by unlabelled phosphate 
groups prior to glucagon challenge. One approach to address 
these issues will be to relate changes in the phosphorylation f
specific peptides in response to glucagon to changes in enzyme 
activities and metabolite l vels. 
A final question relates the functional importance of the 
zonal differences observed in glucagon-stimulated phosphoryl- 
ation. Our knowledge of certain of the peptides (phenylalanine 
hydroxylase, ribosomal protein $6 and the 48- and 46 kDa 
peptides) is so limited that it is difficult to determine the func- 
tional important of zonal differences in their phosphorylation. 
For the other peptides, our results imply that periportal hepa- 
tocytes are the primary site of phosphorylation f the enzymes 
of glycogen metabolism, whereas the phosphorylation of py- 
ruvate kinase and fructose 6-phosphate 2-kinase, both key en- 
zymes in glycolysis, is primarily perivenous in location. 
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